A study investigating the effects of PACAP after developing tolerance (i.e., post-tolerance and not co-administered with morphine) demonstrates that IP administration of the PACAP antagonist, M65, blocked opioid-exaggerated cortical spreading depression, which models migraine aura, in female migraine models (Bertels et al., 2023). This evidence concerns the gene ADCYAP1 and migraine disorder.